当归芍药散调控c-Abl/YAP湍流信号通路防治动脉粥样硬化的机制及配伍特色研究

当归芍药散是临床防治动脉粥样硬化（AS）的有效方剂，但其方剂结构、配伍规律与疗效作用靶点的关系尚不明确，从而影响了该方临床防治AS疗效的进一步提高及化裁应用。 . 本团队在以往研究提出“方-证要素对应”组方规律的基础上，通过前期研究发现了当归芍药散“柔肝缓急”方剂要素具有抑制酪氨酸激酶、调控c-Abl/YAP湍流信号通路等作用，以及全方“柔肝缓急-健脾化浊-活血散瘀”组方原理与AS发病学说高度契合，进而提出“方剂要素-证候要素-效应靶点”紧密相关的研究方案。拟通过动物模型采用全因子实验设计拆方观察当归芍药散调节湍流信号通路等多靶点的作用机制；利用JMP析因分析模块解析当归芍药散及其各方剂要素的主效应与交互效应关系。. 研究具有以下意义：在理论上，揭示当归芍药散防治AS的作用机制，进而阐明当归芍药散的配伍规律及配伍特色；在实践上，为临床防治AS提供本方最佳药物组合方案。

Danggui Shaoyao powder is an effective prescription in treating atherosclerosis (AS). For the unclear relations between prescription compositions, compatibility principle and effect targets, improving therapeutic efficiency and application of reasonable modification in AS have been limited.. In the previous studies, we have proposed the prescription compatibility principle of “correspondence between syndrome and formula factors”. Based on this, we have found that the main components of Danggui Shaoyao powder can inhibit tyrosine kinase, regulate c-Abl/YAP "Oscillatory flow" signal pathway and so on, and the similarities between the whole formula and as pathogenesis theory. Furthermore, the research plan of "formula factors-syndrome factors-effect target" is put forward. In this research, the mechanism of Danggui Shaoyao Powder regulating the "Oscillatory flow" signal pathway and other multi-target points will be observed by using the full factor experimental design of the animal model, and the main effect and interaction relationship of Danggui Shaoyao Powder and its various formula factors will be solved by JMP factorial analysis technology.. The study has the following meanings: Theoretically,illustrating the compatibility principle, characteristics, and mechanism of Danggui Shaoyao powder. Practically, to provide the best Chinese medicine combination regimens for prevention and treatment of atherosclerosis.